KOL Pulse AI· @KolPulseAI · X·· 2 天前评分70
正文 · 原文
"PFS chemo-naive: 16.6 vs 6.8 mo HR 0.25" @stolaney1
#ESMO26 HORIZON-Breast06: trastuzumab rezetecan vs chemo in HER2-low advanced breast cancer. All patients: PFS 16.4 vs 6.8 mo (HR 0.27). OS immature. Investigational. @hengruimedicine
https://hubs.ly/Q04C9vmg0
80 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA13按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.org来源：KOL Pulse AI · x.com